UNITED KINGDOM —Nuformix plc has signed preliminary heads of terms to acquire the entire issued share capital of Biovara Limited via a share-for-share exchange. The proposed transaction is structured as a merger of equals, aiming to integrate Biovara's lipid-based aprepitant formulation, LipAprep, with Nuformix's tranilast-derived candidate, NXP002. Under the proposed terms, the combined group intends to cancel its trading presence on the London Stock Exchange Main Market and seek admission to the AIM market, aligning its corporate structure with its development stage.
The consolidation brings together two clinical-stage assets targeting distinct respiratory indications. LipAprep is positioned for lung cancer-related cough and has completed single-dose Phase 1 testing, whereas NXP002 focuses on idiopathic pulmonary fibrosis and other fibrotic interstitial lung diseases. Both programs leverage modified formulations of established pharmaceutical compounds to improve therapeutic delivery. The agreement incorporates a six-month exclusivity period and establishes a transaction long-stop date of 30 April 2027, with the final structure subject to due diligence, definitive documentation, and regulatory and shareholder approvals.
For the pharmaceutical development sector, the proposed transaction exemplifies a strategic portfolio consolidation among clinical-stage entities seeking to diversify clinical and regulatory risks. By uniting two distinct respiratory programs, the combined entity aims to present a broader pipeline to commercial partners. The planned transition to AIM reflects a broader trend among smaller-cap biotechnology firms seeking regulatory frameworks tailored to growth-stage enterprises with early-stage development pipelines.
Market participants and investors face structural shifts as the transaction progresses toward formal documentation and required shareholder votes, including a potential waiver under Rule 9 of the City Code on Takeovers and Mergers. While ongoing licensing and partnering discussions for NXP002 are expected to continue in parallel, the ultimate valuation and long-term capital strategy will depend on the successful execution of definitive agreements, shareholder consent, and the completion of the AIM admission process.
